Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Receivables (2023 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Change in Receivables for 3 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables fell 18.1% year-over-year to $3.4 million, compared with a TTM value of $9.2 million through Sep 2025, down 23.61%, and an annual FY2024 reading of $7.9 million, up 8.31% over the prior year.
  • Change in Receivables was $3.4 million for Q3 2025 at Fennec Pharmaceuticals, up from $265000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $5.3 million in Q1 2025 and bottomed at $138000.0 in Q1 2023.
  • Average Change in Receivables over 3 years is $2.2 million, with a median of $2.0 million recorded in 2024.
  • Peak annual rise in Change in Receivables hit 957.97% in 2024, while the deepest fall reached 95.92% in 2024.
  • Year by year, Change in Receivables stood at $4.3 million in 2023, then crashed by 95.92% to $175000.0 in 2024, then soared by 1865.71% to $3.4 million in 2025.
  • Business Quant data shows Change in Receivables for FENC at $3.4 million in Q3 2025, $265000.0 in Q2 2025, and $5.3 million in Q1 2025.